The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
- 26 November 2022
- journal article
- research article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 194, 110191
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy StudiesClinical Gastroenterology and Hepatology, 2015
- Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-upJournal of Hepatology, 2012
- Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic SteatohepatitisHepatology, 2009
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced diseaseGut, 2008
- Incidence and natural course of fatty liver in the general population: The Dionysos studyHepatology, 2007
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2006
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡Hepatology, 2006
- The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver DiseaseAnnals of Internal Medicine, 2005
- A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡Hepatology, 2004
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999